RBC Capital analyst Brian Abrahams upgraded Sage Therapeutics to Outperform from Sector Perform with a price target of $60, up from $40.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SAGE:
- No ad com suggests positive potential outcome for Sage’s zura, says BofA
- Biogen, Sage Therapeutics: FDA has no plans to discuss NDA for zuranolone
- Sage Therapeutics: EMA grants Orphan Drug Designation to SAGE-718
- Sage Therapeutics price target raised to $45 from $37 at Mizuho
- Sage Therapeutics reports Q4 EPS ($2.47) , consensus ($2.39)